EGR1 is a transcriptional regulator that binds to specific DNA sequences (5'-GCG(T/G)GGGCG-3') and controls expression of numerous target genes 1. It regulates responses to growth factors, DNA damage, and ischemia, playing critical roles in cell survival, proliferation, and death 1. EGR1 activates tumor suppressors including p53 and TGFB1, and in hepatocellular carcinoma, suppresses aerobic glycolysis by downregulating PFKL, inhibiting HCC cell proliferation and xenograft growth 2. In acute kidney injury, transient EGR1 upregulation promotes tubular epithelial cell regeneration by activating SOX9 and Wnt/β-catenin signaling 3. However, EGR1 also mediates pathological processes: its lactylation drives endothelial glycocalyx degradation in sepsis-induced acute lung injury through heparanase upregulation 4, and it promotes drug resistance in cancer by activating metabolic reprogramming—increasing OXPHOS in ibrutinib-resistant lymphomas via PDP1 5 and forming feedback loops with NNMT in EGFR-TKI-resistant lung cancer 6. Additionally, EGR1 regulates IL33 production in type 2 asthma 7, controls B cell senescence in esophageal cancer immunotherapy resistance 8, and regulates oxidative stress and aldosterone production in adrenal cells 9.